Comparator: Modified Process Vaccine + Comparator: COMVAX™
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Haemophilus Influenzae Type B
Conditions
Haemophilus Influenzae Type B, Hepatitis B
Trial Timeline
Dec 1, 2006 → Jun 1, 2008
NCT ID
NCT00441012About Comparator: Modified Process Vaccine + Comparator: COMVAX™
Comparator: Modified Process Vaccine + Comparator: COMVAX™ is a phase 3 stage product being developed by Merck for Haemophilus Influenzae Type B. The current trial status is completed. This product is registered under clinical trial identifier NCT00441012. Target conditions include Haemophilus Influenzae Type B, Hepatitis B.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00441012 | Phase 3 | Completed |
Competing Products
10 competing products in Haemophilus Influenzae Type B
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Vaxelis + PedvaxHIB | Merck | Approved | 85 |
| Haemophilus influenzae type b (Hib) vaccine | Novartis | Phase 3 | 77 |
| Haemophilus influenzae type b (Hib) vaccine | Novartis | Phase 3 | 77 |
| Haemophilus influenza type b conjugate vaccine | Novartis | Approved | 85 |
| Hib-CRM197 + Hib-TT | Novartis | Phase 3 | 77 |
| Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine) + Hiberix (Haemophilus influenzae type b (Hib) vaccine) | Novartis | Phase 3 | 77 |
| Haemophilus influenzae type b | Novartis | Phase 1 | 33 |
| Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib) + Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib) | Novartis | Phase 3 | 77 |
| Haemophilus influenzae type b vaccine + Commercial Haemophilus influenzae type b vaccine | Novartis | Phase 3 | 77 |
| DTaP-IPV/Hib | Sanofi | Pre-clinical | 22 |